Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Financials

Particulars For the year/period ended (₹ in million)
31-Mar-21 31-Mar-20 31-Mar-19
Total Assets 19,970.75 17,256.04 14,753.95
Total Revenue 18,859.76 15,493.03 8,868.65
Profit After Tax 3,515.81 3,130.98 1,955.92

Important Details about Glenmark Life Sciences IPO

IPO Opening Date Jul 27, 2021
IPO Closing Date Jul 29, 2021
Issue Type Book Built Issue IPO
Face Value ₹2 per equity share
IPO Price ₹695 to ₹720 per equity share
Market Lot 20 Shares
Min Order Quantity 20 Shares
Listing At BSE, NSE

Important Dates

IPO Open Date Jul 27, 2021
IPO Close Date Jul 29, 2021
Basis of Allotment Date Aug 3, 2021
Initiation of Refunds Aug 4, 2021
Credit of Shares to Demat Account Aug 5, 2021
IPO Listing Date Aug 6, 2021

Comments are closed.

How may I assist you?
Hello 👋
Welcome to Mstox. How can we help you?